SLXN
$1.56
Post-MarketAs of Mar 17, 8:00 PM UTC
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors.
Historical Price
Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$1.56
Potential Downside
3048935.9%
Whystock Fair Value$-47561.84
Price
UndervaluedFair ValueOvervalued
Fundamentals
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its propriet...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.20M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
0.00
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.04
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-771.23%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
3.32
